Characterising Neurobiological Abnormalities In Cannabis Use Disorders
Funder
National Health and Medical Research Council
Funding Amount
$731,571.00
Summary
Severe Cannabis Use Disorders cause significant harms to quality of life and outcomes including mental health, cognition, motivation and general well being. We will characterise, for the first time, the neuroadaptations associated with cannabis dependence relative to regular use via advanced imaging techniques and examine links between neural alterations and quality of life. This study will help to identify new treatment targets and develop a new neural model of cannabis addiction.
Selective Modulation Of Neural Network Activity Using Focal Brain Stimulation
Funder
National Health and Medical Research Council
Funding Amount
$531,496.00
Summary
Transcranial magnetic stimulation (TMS) has been touted as a viable treatment for a range of psychiatric and neurological disorders. However, the extent to which localised TMS influences widespread brain networks remains unknown. To fill this gap, we will combine neuroimaging and TMS in healthy adults. The project will provide a scientific foundation for the use of brain stimulation as an effective tool for improving function in a range of clinical conditions.
Developing Robust Biomarkers For Vascular Cognitive Impairment And Dementia: Adding V To The ATN Research Framework
Funder
National Health and Medical Research Council
Funding Amount
$3,289,215.00
Summary
The main objective of this research is to develop biomarkers for vascular dementia. It builds upon the longitudinal studies and international consortia that I lead. The studies will use multimodal MRI, advanced retinal imaging, mass spectrometry and other techniques to establish and validate robust biomarkers of vascular contributions to dementia. The findings will help achieve a definitive diagnosis of vascular dementia and quantify vascular pathology in someone with dementia.
Schizophrenia is classified among the world’s top ten enduring disabilities. Hearing voices are a profound and distressing symptom, which have proven difficult to successfully treat. We plan to use the latest brain imaging techniques and genetic testing to develop the most comprehensive understanding of hearing for voices to date. These data are vital to the development of novel tailored treatment for patients who hear voices.
Perceiving Is Believing: Perceptual Inference Anomalies In Schizophrenia.
Funder
National Health and Medical Research Council
Funding Amount
$344,824.00
Summary
In this study we explore the brain-ability-behaviour relationships that can explain causes of the severe mental illness, schizophrenia. Changes in the brain in schizophrenia affect how people perceive the world around them. Perception relies on our ability to use information in memory to shape what we perceive. We will study brain activity and task abilities that help us to understand where why and how this process becomes disrupted in the brain in persons with schizophrenia.
Identifying Novel Markers To Differentiate Frontotemporal Dementia From Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$603,912.00
Summary
In people under 65 years of age, frontotemporal dementia and Alzheimer's disease are equally common. Distinguishing between these different types of dementia is extremely challenging. Patients can present with similar symptoms, even when the underlying dementia cause (i.e., brain pathology) is different. Inaccurate diagnosis means patients cannot access appropriate treatments, as these become available. I will develop novel tests of social function to improve the diagnosis of dementia syndromes.
Deep Brain Stimulation For Severe Generalised Epilepsy Of Lennox-Gastaut Phenotype
Funder
National Health and Medical Research Council
Funding Amount
$897,972.00
Summary
Deep Brain stimulation (DBS) is an emerging treatment for epilepsy, recently approved for use in Australia on the basis of trials in focal epilepsy showing benefit. The role of DBS in generalised epilepsy is currently unclear. This study tests the effectiveness of DBS in Lennox-Gastaut Syndrome, a severe, medication-resistant generalised epilepsy syndrome.
Patients with schizophrenia differ widely in their symptoms, long-term outcome and response to medication. However, most patients are treated with the same medications and interventions. This study aims to better facilitate the targeting of novel treatments to groups of patients (biotypes) that are likely to benefit most from a treatment. Groups of patients that share distinct patterns of deficits in brain connectivity will be delineated using state-of-the-art white matter imaging techniques.